Healthcare Financial News

Subscribe to enjoy similar stories. Over the last six months, the stock of Narayana Hrudayalaya has risen by over 30% against an 8.3% decline in the Sensex, outperforming the benchmark index by a wide margin. The stock has also been an outlier amid the recent correction, bucking the trend.

Punjab Finance Minister Harpal Singh Cheema presented the state’s FY26 budget on Wednesday, pegged at Rs 2.36 lakh crore with measures to address critical issues like drug abuse, defence, and agriculture. One of the standout proposals is the first-ever «drug census» in Punjab in an effort to gauge the scale of drug usage across the state and evaluating the effectiveness of de-addiction centres. The budget also focuses on providing universal healthcare coverage, improving border security, and addressing environmental concerns such as stubble burning.

Marico Ltd.(up 1.81%), Nakoda Group Of Industries Ltd.(up 1.72%), Sheetal Cool Products Ltd.(up 1.29%), Nakoda Group Of Industries Ltd.(up 1.27%), Hatsun Agro Products Ltd.(up 0.98%), Bikaji Foods International Ltd.(up 0.93%), Heritage Foods Ltd.(up 0.89%), LT Foods Ltd.(up 0.54%), JHS Svendgaard Laboratories Ltd.(up 0.49%) and Procter & Gamble Hygiene & Healthcare Ltd.(up 0.46%) were among the top gainers.

Gnanamma Healthcare Centre announced its transition to becoming a near net-zero electricity health facility. This milestone has been achieved through the recent installation of a 6.05kW solar power plant with battery energy storage, which now meets up to 100% of the facilities' electricity needs. The green facility was launched in the presence of Dr Mehriba K. Sohliya, District Medical, Health Officer, West Khasi Hills, hospital administration and WRI India. With technical support from WRI India, the facility has installed a solar power plant, battery storage, and energy-efficient appliances, including indoor lights, ceiling fans, flood lights, water purifier, water heater, and an autoclave. This transformation ensures that Gnanamma Healthcare Centre operates almost entirely on renewable energy, setting a precedent for sustainable healthcare in the region.

Subscribe to enjoy similar stories. Wipro GE Healthcare, the 35-year-old joint venture between GE HealthCare and Wipro Enterprises, has started rolling out its $1 billion investment plan to expand manufacturing in India and boost exports, confident that it can dodge the impact of reciprocal tariffs that the US may impose on India’s medtech industry. The company expects to make about 70% of its products for the Indian market locally by 2030, a top executive said, compared with 40-45% currently.

Kat Abughazaleh announced her candidacy for Illinois’ 9th Congressional District. She has challenged long-time Democratic incumbent Jan Schakowsky in what could be the district’s first competitive primary since 1998. Abughazaleh, aged 26, is a freelance content creator with no prior experience in politics. She does not currently live in the district and has been in Illinois for less than a year, stated the media reports. However, she is determined to disrupt the status quo. As per a Rolling Stone report, she cited frustration with the Democratic Party’s response to the challenges of everyday Americans. Kat said that the public is in an emergency and that the only way to fight authoritarianism is to be loud, and proud every single day.

India for a long time, often shares her observations on cultural differences between the two countries. In a recent video, she compared the healthcare systems of India and the USA, highlighting key differences in wait times, costs, and accessibility—points that many viewers agreed with. She began by discussing the waiting period for medical services. In the USA, an appointment with a general physician typically takes 2 to 4 weeks, whereas in India, walk-in consultations are available the same day. Specialist consultations in the USA require a wait of 1 to 3 months, while in India, they can usually be scheduled within a week. Elective surgeries, which take 3 to 6 months in the USA, are completed within 1 to 4 weeks in India. She also addressed the stark contrast in costs. In India, a doctor’s visit costs between $7 and $17 (approximately ₹600 to ₹1,500), whereas in the USA, it ranges from $150 to $600 (₹13,000 to ₹51,000). The cost of a one-night hospital stay is about $3,000 (₹2.56 lakh) in the USA, while in India, it is under $80 (₹7,000). Medical insurance in the USA costs between ₹68,000 and ₹1.28 lakh per month, compared to India, where it ranges from ₹2,000 to ₹5,000.

Dental care provider Clove Dental announced the opening of its 600th clinic in Gurugram on its 14th anniversary. Established in 2011, Clove Dental has grown into a network spanning over 26 cities, having served more than 3 million satisfied patients. Similar to all our existing clinics, the new Gurugram clinic is equipped with state-of-the-art technology and adheres to strict safety and hygiene protocols. Louis Shakinovsky, Group Chairman of Global Dental Services, said in a statement, «Credibility is doing what you say. Our Clove team has unquestionably done this convincingly. Since its inception in 2011, Clove Dental has been on a mission to transform dental care in India. A few years ago, I had envisioned an ambitious goal to reach 600 clinics. It makes me feel joyous to see this become a reality.” Amarinder Singh, Founder & CEO of Clove Dental, said, „At Clove Dental, we believe that trust is the foundation of effective healthcare. Our commitment to transparency ensures that patients are fully informed about their treatment options and computer-controlled pricing. We provide clear communication, and detailed treatment plans for all procedures, ensuring complete compliance to the measures laid by the Dental Council of India. At Clove Dental, we implement world-class quality control processes, leveraging AI and computer vision for unmatched sterilization adherence—pioneering a first-of-its-kind standard in global dental care.“

BEIJING — Alibaba-affiliate Ant Group is using both Chinese and U.S.-made semiconductors for building more efficient artificial intelligence models, according to a source familiar with the matter.

growth story among emerging markets, according to Gustavo Medeiros, Head of Research at Ashmore Group, a global investment manager. While the firm had taken a cautious tactical approach over the past year, it is now gradually rebuilding exposure to Indian equities. Speaking in an interaction with ETNow, Medeiros said, “Absolutely, the world loves India. It is the most exciting structural story in emerging markets.” He added that India's appeal has grown significantly over the last decade thanks to “economic policies [that] have been much more pro-market.”

“India's consumption has been a robust long-term story. As economic development accelerates and the middle class grows, the potential for further expansion in the consumer market is set to increase significantly,” says Harshad Patil, CIO, Tata AIA. In an interview with ETMarkets, Patil said: “We see strong potential in some sectors such as Retail, Quick Commerce, Healthcare, FinTech ,Travel and Hospitality, Consumer Durables and Automobiles,” Edited excerpts: Thanks for taking the time out. After a nearly 6% drop in February 2025, volatility continues in March. What is weighing on markets? In the month of March, Indian equities have been under pressure due to tariff concerns. The recent announcement of new tariffs by the U.S. President, including a 25% levy on select imports from Mexico and Canada, has led to a surge in market volatility across the globe.

Apollo Hospitals shares will be in focus on Monday after its subsidiary, Apollo Healthco (AHL), announced plans to acquire an additional 11.2% stake in Keimed Pvt Ltd for Rs 625.43 crore from promoter Shobana Kamineni. In a regulatory filing, Apollo Hospitals stated that its board had approved AHL’s acquisition of 11.2% of Keimed’s issued and paid-up share capital in two tranches. The purchase will be made from Shobana Kamineni, a related party, for Rs 625.43 crore.

Adani Green, Adani Enterprises, NCC, Dr. Reddy’s, Max Healthcare, and Apollo Hospitals will be in focus due to key developments. Godrej Properties: Godrej Properties has acquired 10 acres of land in Bengaluru, with an estimated revenue potential of Rs 2,500 crore. The proposed development will have a saleable area of about 1.5 million square feet and will offer homes in various configurations, catering to different segments of homebuyers.

DSP Small Cap Fund, one of the oldest in the small-cap category since its launch in June 2007, remains among the few funds in its segment with no exposure to large-cap stocks. It continues to allocate around 90% of its corpus to small cap stocks, with the rest split between cash holdings (slightly higher than usual) and mid-cap stocks. This is despite the Nifty Small Cap index falling 21%so far in 2025, and 24% from its peak in December 2024. Of course, Sambre has paid the price. So far this year, the scheme has delivered a negative return of 19.2%. Acknowledging the risks of small-cap investing, Sambre remains firm in his approach: if investors seek a small-cap fund, they should expect a true, small-cap experience. Previously the sole manager of the fund, he now oversees DSP’s equity funds, which have a combined corpus of approximately Rs.1.08 trillion. Additionally, he co-manages three schemes, including the mid-cap and small-cap funds, worth Rs.30,000 crore.

Calculus Group has signed a memorandum with NGO HRDS India to deploy AI-enabled tools for developing a digital ecosystem in rural areas, a top company official said. As per the agreement, Calculus Group will fulfil projects undertaken by HRDS India in the field of rural development, where technology will play a distinct role in social enablement. Calculus Group founder and CEO Sooraj Vasudevan said his company builds technology ecosystems for corporates and telecommunication companies and governments globally. «Through this Rs 1,000 crore MoU with HRDS we are trying to emulate or replicate that in the context of the rural population and bring whatever pieces of technology needed to roll out and make an impact. It doesn't have to be a particular product,» Vasudevan told PTI.

Subscribe to enjoy similar stories. Communication is key to creating a healthy bond between doctors and patients. Doctors have a message for patients: Trust is a two-way street.

Subscribe to enjoy similar stories. Private credit funding, in which lenders and borrowers directly negotiate financing without engaging an intermediary, is increasing in size and complexity, as companies look to diversify their source of funding, Pramod Kumar, chief executive officer and head of investment banking - India at Barclays Plc. Barclays, which has been quite active in the private credit space over the past few years, is looking at big-ticket transactions.

Like the earlier month, the fortnight (ending March 15) sell-off affected nearly all sectors in the market, with the exception of metals. Metal stocks stood out as they attracted investments worth Rs 1,100 crore, making them the only sector to buck the trend. This was not the case in the preceding period.

As many hospitals are planning to double their capacity over the next three to five years, Shibani Kurian, Head — Equity Research and Fund Manager, Kotak Mahindra AMC, estimates that the growth of hospital companies will outpace that of diagnostics and pharmaceutical companies. In this interview with ET Markets, Kurian also talks about investing in pharma stocks amid Trump's tariff threats. Edited excerpts from a chat:

Eli Lilly on Thursday introduced its globally popular anti-diabetes and obesity drug Mounjaro (tirzepatide) in India, kicking off a raft of planned launches in this therapeutic area over the next few months. At the starting dose of 2.5 mg, the drug will cost Rs 14,000 a month, a company official said. The 2.5 mg vial and 5 mg vial will be available at Rs 3,500 and Rs 4,375, respectively. A spokesperson said as Mounjaro (tirzepatide) is a prescription-based product, the treatment plan is determined by a healthcare professional and varies for each individual. Eli Lilly will sell only Mounjaro for both obesity and diabetes in India unlike Zepbound, which is the prescribed obesity drug in the US. The key ingredient tirzepatide is the same for both brands. «The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India,» Winselow Tucker, president and general manager, Lilly India, said in a statement. «Lilly is committed to collaborating with the government and industry to promote awareness and improve the prevention and management of these diseases.»

Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes. U.S.-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers' valuations.